Market Research Reports and Industry Reports

Gastroparesis - Pipeline Review, H2 2015

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Gastroparesis - Pipeline Review, H2 2015

Summary

Global Markets Directs, Gastroparesis - Pipeline Review, H2 2015, provides an overview of the Gastroparesiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroparesis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroparesis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroparesis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroparesis - Overview 7
Pipeline Products for Gastroparesis - Comparative Analysis 8
Gastroparesis - Therapeutics under Development by Companies 9
Gastroparesis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Gastroparesis - Products under Development by Companies 13
Gastroparesis - Companies Involved in Therapeutics Development 14
GlaxoSmithKline Plc 14
RaQualia Pharma Inc. 15
Gastroparesis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 23
camicinal - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ETX-101 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ETX-301 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NG-101 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RQ-00000010 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RQ-00201894 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
velusetrag hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gastroparesis - Recent Pipeline Updates 31
Gastroparesis - Dormant Projects 34
Gastroparesis - Product Development Milestones 35
Featured News & Press Releases 35
May 18, 2015: Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of Gastroparesis in "Poster of Distinction" at Digestive Disease Week (DDW) 2015 35
Mar 12, 2015: Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of Gastroparesis 36
Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA 37
Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis 37
Sep 14, 2012: RaQualia Pharmas Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List Of Tables

Number of Products under Development for Gastroparesis, H2 2015 7
Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2015 14
Gastroparesis - Pipeline by RaQualia Pharma Inc., H2 2015 15
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Stage and Target, H2 2015 18
Number of Products by Stage and Mechanism of Action, H2 2015 20
Number of Products by Stage and Route of Administration, H2 2015 21
Number of Products by Stage and Molecule Type, H2 2015 22
Gastroparesis Therapeutics - Recent Pipeline Updates, H2 2015 31
Gastroparesis - Dormant Projects, H2 2015 34

List Of Figures

Number of Products under Development for Gastroparesis, H2 2015 7
Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Top 10 Targets, H2 2015 17
Number of Products by Stage and Top 10 Targets, H2 2015 17
Number of Products by Top 10 Mechanism of Actions, H2 2015 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 19
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 21
Number of Products by Stage and Top 10 Molecule Types, H2 2015 22

Gastroparesis Global Clinical Trials Review, H2, 2016

Gastroparesis Global Clinical Trials Review, H2, 2016GlobalDatas clinical trial report, Gastroparesis Global Clinical Trials Review, H2, 2016 provides an overview of Gastroparesis clinical trials scenario. This report provides top line

USD 2500View Report

Diabetic Gastroparesis  - Epidemiology Forecast To 2023

DelveInsight Diabetic Gastroparesis - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Diabetic Gastroparesis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

USD 2750View Report

Diabetic Gastroparesis  - Market Insights, Epidemiology and Market Forecast-2023

DelveInsights Diabetic Gastroparesis - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Diabetic Gastroparesis for the seven major markets

USD 4950View Report

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016Global Markets Directs, Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016, provides in

USD 3500View Report

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016Global Markets Directs, Acetyl CoA Carboxylase 2 (ACC2 or ACC

USD 3500View Report

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016Global Markets Directs, Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016, provides in depth analysis

USD 3500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprise Wide Licence    $ 6000
$ 2000

Reports Details

Published Date : Sep 2015
No. of Pages :40
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

,
 

We Accept

payment